Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07170345

Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Hepatocellular carcinoma (HCC) is a common malignancy in China with a high mortality rate. Its early recurrence and long-term prognosis are closely associated with tumor aggressiveness. Microvascular invasion (MVI), defined as the presence of tumor cells within small branches of the portal or hepatic veins, is a key indicator of malignant biological behavior in HCC. Clinically, MVI is strongly correlated with postoperative early recurrence and serves as an important factor in determining surgical margin extension, adjuvant therapy, and postoperative management strategies.

At present, definitive diagnosis of MVI still relies on postoperative pathological examination, and stable, effective preoperative assessment methods are lacking. Although some studies have attempted to predict MVI using preoperative imaging features, their clinical translation remains limited by poor generalizability, weak interpretability, and insufficient cross-center adaptability.

This study aims to leverage multiphase preoperative CT imaging, artificial intelligence techniques, and clinical prior knowledge to develop a high-performance, generalizable, and interpretable computer-aided diagnostic system for preoperative prediction of HCC-MVI. An observational, prospective evaluation will be conducted to assess system performance and to facilitate the clinical translation of intelligent diagnostic technologies in real-world practice.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Meng Chao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China

Loading trial locations.

About this study

Hepatocellular carcinoma (HCC) is a common malignancy in China with a high mortality rate. Early recurrence and long-term prognosis are closely linked to tumor aggressiveness. Microvascular invasion (MVI), defined as the presence of tumor cells within small branches of the portal or hepatic veins, is a critical marker of malignant biological behavior. Clinically, MVI is strongly associated with early postoperative recurrence and serves as an important reference for determining surgical margin extension, adjuvant treatment, and postoperative management strategies. At present, definitive diagnosis of MVI still relies on postoperative pathological examination, and reliable preoperative assessment methods are lacking. Although prior studies have attempted to predict MVI using preoperative imaging, their clinical application remains limited by poor generalizability, weak interpretability, and insufficient cross-center adaptability.

This study aims to develop a high-performance, generalizable, and interpretable computer-aided diagnostic (CAD) system for preoperative prediction of HCC-MVI using multiphase CT imaging, artificial intelligence techniques, and clinical prior knowledge. The system will be evaluated prospectively in an observational, multicenter clinical study to assess its diagnostic value and clinical applicability.

The CAD system integrates three categories of imaging features: (1) high-level representations automatically extracted by deep neural networks; (2) predefined radiomics features such as tumor morphology, texture, and intensity distributions; and (3) structured prior features derived from radiological expertise, including tumor margin blurriness and spatial relationships with adjacent portal veins. Sparse constraints and redundancy suppression mechanisms will be applied to identify stable and efficient MVI-related representations. In addition, the system adopts a spatial domain strategy covering tumor, peritumoral, and distant regions, in order to capture invasion patterns from both local morphology and microenvironmental context, thereby constructing reproducible and clinically interpretable imaging biomarkers.

To overcome the limitations of single-domain models, the system employs a multi-source heterogeneous fusion strategy that integrates morphological-textural features, dynamic enhancement patterns, and spatial graph structures. The model architecture combines convolutional neural networks (CNNs) to capture fine-grained textures, Transformer modules to model long-range dependencies, and graph neural networks (GNNs) to represent tumor-vascular topological relationships. This hybrid approach enables comprehensive understanding of both local details and global structures. Furthermore, the model incorporates uncertainty quantification and attention-like mechanisms to dynamically adjust prediction confidence and generate saliency heatmaps. These outputs are designed to enhance clinicians' interpretability and trust in the system. An interactive visualization interface will also be developed to support risk interpretation and surgical planning.

The study will conduct a prospective observational validation across multiple clinical centers, with unified inclusion/exclusion criteria and standardized data collection protocols. Model predictions will be blindly compared against postoperative pathological results. In addition to conventional metrics (accuracy, sensitivity, specificity, and AUC), the study will observationally evaluate the impact of model-based predictions on preoperative risk stratification and surgical decision-making. By testing the system across diverse patient populations, the study aims to confirm its generalizability, clinical utility, and potential for real-world translation of intelligent diagnostic technologies.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Confirmed diagnosis of hepatocellular carcinoma (HCC) according to the Chinese Clinical Practice Guidelines for Primary Liver Cancer.
  • Eligible for surgical intervention (hepatic resection or liver transplantation) according to the Chinese Clinical Practice Guidelines for Cancer, including stages Ia, Ib, and IIa.
  • Preoperative imaging examination performed within 1 month before surgery.
  • Availability of histopathological evaluation with documented microvascular invasion (MVI) status.

Exclusion criteria

  • History of prior antitumor treatment, including preoperative surgical intervention, transarterial chemoembolization (TACE), radiofrequency ablation (RFA), systemic therapy, or any other preoperative intervention.
  • Presence of major vascular invasion, bile duct invasion/thrombosis, extrahepatic metastasis, or lymph node involvement.
  • Diffuse hepatocellular carcinoma or tumor rupture with hemorrhage.
  • Lack of key data required for primary analysis.
  • Poor image quality that prevents reliable qualitative or radiomics analysis.

Treatment and study plan

Computer-Aided Diagnosis System for Preoperative Prediction of MVI in HCC

Diagnostic Test

This intervention is an artificial intelligence-based computer-aided diagnosis (CAD) system developed to predict microvascular invasion (MVI) in patients with hepatocellular carcinoma using preoperative multiphase CT imaging. The system integrates deep learning, radiomics, and expert-defined imaging features to provide risk assessment and visualization of MVI prior to surgery. In this study, the CAD system will be evaluated retrospectively and prospectively in an observational manner only. The results will not influence clinical decision-making or patient management, and all treatments will follow standard of care.

Primary outcomes

  1. Area Under the Receiver Operating Characteristic Curve (AUC)

    Time frame: Within 1 month after surgery

    The AUC will be calculated by comparing CAD system predictions with the reference standard of postoperative pathological diagnosis of microvascular invasion in hepatocellular carcinoma.

  2. Accuracy

    Time frame: Within 1 month after surgery

    Accuracy will be defined as the proportion of correctly classified cases (both MVI-positive and MVI-negative) by the CAD system compared with postoperative pathology.

Secondary outcomes

  1. Sensitivity

    Time frame: Within 1 month after surgery

    Sensitivity will be calculated as the proportion of true positive MVI cases correctly identified by the CAD system compared with postoperative pathology.

  2. Specificity

    Time frame: Within 1 month after surgery

    Specificity will be calculated as the proportion of true negative MVI cases correctly identified by the CAD system compared with postoperative pathology.

  3. Calibration

    Time frame: Within 1 month after surgery

    Calibration performance will be assessed using calibration curves, Hosmer-Lemeshow goodness-of-fit tests, and Brier scores, to determine agreement between predicted probabilities and observed MVI outcomes.

Other outcomes

  1. Processing Time

    Time frame: Within 1 month after surgery

    Average computational time required for the CAD system to generate predictions and visualization outputs will be recorded to assess feasibility for integration into clinical workflow.

  2. Physician Confidence Score

    Time frame: Within 1 month after surgery

    Physician Confidence Score will be measured using a questionnaire that asks physicians to rate their confidence in assessing patient risk after reviewing CAD-generated probability scores and saliency maps. Responses will be collected on a 5-point Likert scale (1 = not confident at all, 2 = slightly confident, 3 = moderately confident, 4 = confident, 5 = very confident). The score will be recorded as the numerical Likert scale value selected by each physician.

Study contacts

Contact information is provided by the study sponsor or research team.

Di Dong, Ph.D.

CONTACT

[email protected]

+86 13811833760

Mengjie Fang, Ph.D.

CONTACT

[email protected]

+86 18500909634

Sponsors and collaborators

Lead sponsor

Chinese Academy of Sciences

Other Gov

Collaborators

  • Beijing Tsinghua Changgeng Hospital
  • Beijing YouAn Hospital
  • Dazhou Central Hospital
  • Eastern Hepatobiliary Surgery Hospital
  • Fifth Affiliated Hospital, Sun Yat-Sen University
  • First Affiliated Hospital of Guangxi Medical University
  • First Affiliated Hospital of Kunming Medical University
  • First Affiliated Hospital of Wenzhou Medical University
  • Guangdong Provincial Hospital of Traditional Chinese Medicine
  • Guizhou Provincial People's Hospital
  • Henan Provincial People's Hospital
  • Meng Chao Hepatobiliary Hospital of Fujian Medical University
  • Peking Union Medical College Hospital
  • Shengjing Hospital
  • The First People's Hospital of Yunnan
  • West China Hospital
  • Yunnan Cancer Hospital
  • ZhuHai Hospital
  • Zhujiang Hospital

Registry information

Official study title

Development of a Computer-Aided Diagnosis System for Hepatocellular Carcinoma Microvascular Invasion Based on Preoperative Image Analysis

Acronym: HCC-MVI-CAD

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Sep 12, 2025
Registry last updated
Sep 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.